Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Factor Xa Inhibitors"" wg kryterium: Temat


Tytuł :
Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.
Autorzy :
Parsels KA; Upstate University Hospital, Department of Pharmacy, Syracuse, NY, USA. Electronic address: .
Seabury RW; Upstate University Hospital, Department of Pharmacy, Syracuse, NY, USA; Upstate Medical University, Department of Medicine, Syracuse, NY, USA.
Zyck S; Upstate University Hospital, Department of Neurosurgery, Syracuse, NY, USA.
Miller CD; Upstate University Hospital, Department of Pharmacy, Syracuse, NY, USA; Upstate Medical University, Department of Medicine, Syracuse, NY, USA.
Krishnamurthy S; Upstate Medical University, Department of Medicine, Syracuse, NY, USA; Upstate University Hospital, Department of Neurosurgery, Syracuse, NY, USA.
Darko W; Upstate University Hospital, Department of Pharmacy, Syracuse, NY, USA; Upstate Medical University, Department of Medicine, Syracuse, NY, USA.
Probst LA; Upstate University Hospital, Department of Pharmacy, Syracuse, NY, USA; Upstate Medical University, Department of Medicine, Syracuse, NY, USA.
Latorre JG; Upstate Medical University, Department of Medicine, Syracuse, NY, USA; Upstate University Hospital, Department of Neurology, Syracuse, NY, USA.
Cwikla GM; Upstate University Hospital, Department of Pharmacy, Syracuse, NY, USA.
Feldman EA; Upstate University Hospital, Department of Pharmacy, Syracuse, NY, USA.
Pokaż więcej
Źródło :
The American journal of emergency medicine [Am J Emerg Med] 2022 May; Vol. 55, pp. 16-19. Date of Electronic Publication: 2022 Feb 24.
Typ publikacji :
Journal Article
MeSH Terms :
Factor Xa Inhibitors*/adverse effects
Rivaroxaban*/adverse effects
Anticoagulants/adverse effects ; Blood Coagulation Factors/therapeutic use ; Cohort Studies ; Factor Xa ; Hemorrhage ; Humans ; Intracranial Hemorrhages/chemically induced ; Intracranial Hemorrhages/drug therapy ; Pyrazoles ; Pyridones ; Recombinant Proteins ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Immediate postprocedure anticoagulation with factor Xa inhibitors of venous stents for nonthrombotic venous lesions does not increase stent patency.
Autorzy :
Pappas PJ; Center for Vein Restoration, Greenbelt, Md; Center for Vascular Medicine, Greenbelt, Md. Electronic address: .
Lakhanpal G; Center for Vein Restoration, Greenbelt, Md; Center for Vascular Medicine, Greenbelt, Md.
Lakhanpal S; Center for Vein Restoration, Greenbelt, Md; Center for Vascular Medicine, Greenbelt, Md.
Sulakvelidze L; Center for Vascular Medicine, Greenbelt, Md.
Tran M; Center for Vascular Medicine, Greenbelt, Md.
Shetty A; Center for Vascular Medicine, Greenbelt, Md.
Kennedy R; Center for Vascular Medicine, Greenbelt, Md.
Pokaż więcej
Źródło :
Journal of vascular surgery. Venous and lymphatic disorders [J Vasc Surg Venous Lymphat Disord] 2022 May; Vol. 10 (3), pp. 633-639.e1. Date of Electronic Publication: 2021 Nov 12.
Typ publikacji :
Journal Article
MeSH Terms :
Factor Xa Inhibitors*/adverse effects
Rivaroxaban*
Adult ; Aged ; Anticoagulants/adverse effects ; Female ; Humans ; Iliac Vein/surgery ; Middle Aged ; Retrospective Studies ; Stents ; Time Factors ; Treatment Outcome ; Vascular Patency
Czasopismo naukowe
Tytuł :
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
Autorzy :
Piccini JP; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA; Duke University Medical Center, Durham, NC, USA. Electronic address: .
Caso V; University of Perugia Stroke Unit, Perugia, Italy.
Connolly SJ; Population Health Research Institute, McMaster University, Hamilton, ON, Canada; Hamilton Health Services, Hamilton, ON, Canada.
Fox KAA; Division of Medical and Radiological Sciences, University of Edinburgh, Edinburgh, UK.
Oldgren J; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Jones WS; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA; Duke University Medical Center, Durham, NC, USA.
Gorog DA; National Heart and Lung Institute, Imperial College London, London, UK; University of Hertfordshire, Hatfield, UK.
Durdil V; University Hospital Motol, Prague, Czech Republic.
Viethen T; Bayer, Wuppertal, Germany.
Neumann C; Bayer, Wuppertal, Germany.
Mundl H; Bayer, Wuppertal, Germany.
Patel MR; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA; Duke University Medical Center, Durham, NC, USA.
Pokaż więcej
Corporate Authors :
PACIFIC-AF Investigators
Źródło :
Lancet (London, England) [Lancet] 2022 Apr 09; Vol. 399 (10333), pp. 1383-1390. Date of Electronic Publication: 2022 Apr 03.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Anticoagulants*/adverse effects
Atrial Fibrillation*/drug therapy
Factor Xa Inhibitors*/adverse effects
Aged ; Double-Blind Method ; Female ; Hemorrhage/chemically induced ; Humans ; Male ; Pyrazoles/adverse effects ; Pyridones/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
An integration strategy combined progressive multivariate statistics with anticoagulant activity evaluation for screening anticoagulant quality markers in Chinese patent medicine.
Autorzy :
Du KZ; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Tianjin Key Laboratory of Phytochemistry and Pharmaceutical Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Cui Y; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Tianjin Key Laboratory of Phytochemistry and Pharmaceutical Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Chen S; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Tianjin Key Laboratory of Phytochemistry and Pharmaceutical Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Yang R; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Tianjin Key Laboratory of Phytochemistry and Pharmaceutical Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Shang Y; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Tianjin Key Laboratory of Phytochemistry and Pharmaceutical Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Wang C; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Tianjin Key Laboratory of Phytochemistry and Pharmaceutical Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Yan Y; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Tianjin Key Laboratory of Phytochemistry and Pharmaceutical Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Li J; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Chang YX; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Tianjin Key Laboratory of Phytochemistry and Pharmaceutical Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. Electronic address: .
Pokaż więcej
Źródło :
Journal of ethnopharmacology [J Ethnopharmacol] 2022 Apr 06; Vol. 287, pp. 114964. Date of Electronic Publication: 2022 Jan 03.
Typ publikacji :
Journal Article
MeSH Terms :
Anticoagulants/*pharmacology
Drugs, Chinese Herbal/*pharmacology
Factor Xa Inhibitors/*pharmacology
Thrombin/*antagonists & inhibitors
Animals ; Anticoagulants/chemistry ; Cattle ; Chromatography, High Pressure Liquid ; Drugs, Chinese Herbal/chemistry ; Factor Xa Inhibitors/chemistry ; Molecular Docking Simulation ; Quality Control ; Tandem Mass Spectrometry
Czasopismo naukowe
Tytuł :
Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis.
Autorzy :
Al Rowily A; School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, Sir Robert Aitken Institute for Medical Research, University of Birmingham, Birmingham, B15 2TT, UK.; Pharmaceutical Care Department, King Fahad Military Medical Complex (KFMMC), Medical Department, Ministry of Defence, Dhahran, Saudi Arabia.
Jalal Z; School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, Sir Robert Aitken Institute for Medical Research, University of Birmingham, Birmingham, B15 2TT, UK.
Price MJ; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.; NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Abutaleb MH; Pharmaceutical Care Department, King Fahad Central Hospital, Jazan Health Affairs, Ministry of Health, Jazan, Saudi Arabia.
Almodiaemgh H; Pharmaceutical Care Department, King Abdulaziz Medical City, King Abdullah International Medical Research Center/King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Al Ammari M; Pharmaceutical Care Department, King Abdulaziz Medical City, King Abdullah International Medical Research Center/King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Paudyal V; School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, Sir Robert Aitken Institute for Medical Research, University of Birmingham, Birmingham, B15 2TT, UK. .
Pokaż więcej
Źródło :
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2022 Apr; Vol. 78 (4), pp. 623-645. Date of Electronic Publication: 2021 Dec 22.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Anticoagulants*/adverse effects
Atrial Fibrillation*/drug therapy
Factor Xa Inhibitors*/therapeutic use
Administration, Oral ; Humans ; Medication Errors
Czasopismo naukowe
Tytuł :
Two Cases of Acute Direct Oral Anticoagulant Overdose Without Adverse Effect.
Autorzy :
Ha CJ; Columbia University Vagelos College of Physicians and Surgeons.
Harmouche E; Department of Emergency Medicine, Maimonides Medical Center.
Howland MA; NYC Poison Control Center.; St. John's University College of Pharmacy and Health Professions.
Su MK; NYC Poison Control Center.; Ronald O. Perelman Department of Emergency Medicine, New York University Grossman School of Medicine, New York City, NY.
Pokaż więcej
Źródło :
Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2022 Mar 01; Vol. 44 (2), pp. e447-e449.
Typ publikacji :
Journal Article
MeSH Terms :
Drug-Related Side Effects and Adverse Reactions*/drug therapy
Factor Xa Inhibitors*
Administration, Oral ; Anticoagulants/adverse effects ; Blood Coagulation ; Blood Coagulation Tests ; Child ; Humans ; Rivaroxaban/adverse effects
Czasopismo naukowe
Tytuł :
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
Autorzy :
von Horn H; Department of Molecular Medicine and Surgery, Karolinska Institutet & Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden.
Rasmusson A; Department of Molecular Medicine and Surgery, Karolinska Institutet & Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden.
Söderblom L; Department of Molecular Medicine and Surgery, Karolinska Institutet & Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden.
Malmström RE; Department of Medicine Solna, Karolinska Institutet & Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.
Antovic J; Department of Molecular Medicine and Surgery, Karolinska Institutet & Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Źródło :
International journal of laboratory hematology [Int J Lab Hematol] 2022 Feb; Vol. 44 (1), pp. 163-167. Date of Electronic Publication: 2021 Sep 15.
Typ publikacji :
Journal Article
MeSH Terms :
Blood Coagulation Tests/*methods
Factor Xa Inhibitors/*pharmacokinetics
Pyrazoles/*pharmacokinetics
Pyridones/*pharmacokinetics
Rivaroxaban/*pharmacokinetics
Stroke/*blood
Stroke/*prevention & control
Venous Thromboembolism/*blood
Venous Thromboembolism/*prevention & control
Atrial Fibrillation/blood ; Atrial Fibrillation/complications ; Blood Coagulation Tests/standards ; Chromatography, Liquid ; Clinical Decision-Making ; Disease Management ; Disease Susceptibility ; Drug Monitoring/methods ; Factor Xa Inhibitors/administration & dosage ; Heparin, Low-Molecular-Weight ; Humans ; Pyrazoles/administration & dosage ; Pyridones/administration & dosage ; Reproducibility of Results ; Rivaroxaban/administration & dosage ; Sensitivity and Specificity ; Stroke/diagnosis ; Stroke/etiology ; Tandem Mass Spectrometry ; Venous Thromboembolism/diagnosis ; Venous Thromboembolism/etiology
Czasopismo naukowe
Tytuł :
Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria.
Autorzy :
Dev P; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA. .
Abousaab C; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Zhou C; UT Southwestern Medical School, UT Southwestern Medical Center, Dallas, TX, USA.
Sarode R; Department of Pathology and Internal Medicine (Hematology/Oncology), UT Southwestern Medical Center, Dallas, TX, USA.
Pokaż więcej
Źródło :
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2022 Feb; Vol. 53 (2), pp. 249-256. Date of Electronic Publication: 2021 Aug 09.
Typ publikacji :
Journal Article
MeSH Terms :
Blood Coagulation Factors*/therapeutic use
Factor Xa Inhibitors*/adverse effects
Anticoagulants/adverse effects ; Factor Xa ; Gastrointestinal Hemorrhage/chemically induced ; Gastrointestinal Hemorrhage/drug therapy ; Humans ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Can We Improve on the Rapid Assessment of Clinically Relevant Levels of Direct Acting Oral Anticoagulants (DOAC)?
Autorzy :
Walenga JM; Cardiovascular Institute, 2456Loyola University Chicago, Chicago, Illinois, United States.
Pokaż więcej
Źródło :
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis [Clin Appl Thromb Hemost] 2022 Jan-Dec; Vol. 28, pp. 10760296221096422.
Typ publikacji :
Editorial
MeSH Terms :
Anticoagulants*/pharmacology
Anticoagulants*/therapeutic use
Factor Xa Inhibitors*/pharmacology
Factor Xa Inhibitors*/therapeutic use
Administration, Oral ; Humans
Opinia redakcyjna
Tytuł :
The affordability of adding a direct-acting oral anticoagulant to the national list of essential medicine for patients with non-valvular atrial fibrillation in Thailand: a budget impact analysis.
Autorzy :
Dilokthornsakul P; Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.
Permsuwan U; Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
Pokaż więcej
Źródło :
Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2022 Jan; Vol. 22 (1), pp. 93-100. Date of Electronic Publication: 2021 Feb 10.
Typ publikacji :
Journal Article
MeSH Terms :
Atrial Fibrillation*/drug therapy
Factor Xa Inhibitors*/economics
Factor Xa Inhibitors*/therapeutic use
Costs and Cost Analysis ; Drugs, Essential ; Humans ; Thailand
Czasopismo naukowe
Tytuł :
Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital.
Autorzy :
Clapham RE; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Speed V; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.; Institute of Pharmaceutical Sciences, King's College London, London, UK.
Czuprynska J; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Gazes A; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Guppy S; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Patel RK; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Rea C; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Vadher B; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Arya R; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Roberts LN; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2022 Jan; Vol. 196 (1), pp. e3-e6. Date of Electronic Publication: 2021 Aug 05.
Typ publikacji :
Letter
MeSH Terms :
Factor Xa Inhibitors/*therapeutic use
Rivaroxaban/*therapeutic use
Venous Thrombosis/*drug therapy
Disease Management ; Factor Xa Inhibitors/administration & dosage ; Factor Xa Inhibitors/adverse effects ; Humans ; Rivaroxaban/administration & dosage ; Rivaroxaban/adverse effects ; Treatment Outcome ; Venous Thrombosis/diagnosis ; Venous Thrombosis/etiology
Opinia redakcyjna
Tytuł :
Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
Autorzy :
May CC; Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Electronic address: .
Cua S; The Ohio State University College of Medicine, Columbus, Ohio, USA.
Smetana KS; Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Powers CJ; Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Pokaż więcej
Źródło :
World neurosurgery [World Neurosurg] 2022 Jan; Vol. 157, pp. e357-e363. Date of Electronic Publication: 2021 Oct 14.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Enoxaparin/*blood
Factor Xa Inhibitors/*blood
Hemorrhage/*blood
Neurosurgical Procedures/*trends
Pre-Exposure Prophylaxis/*trends
Adult ; Aged ; Anticoagulants/administration & dosage ; Anticoagulants/adverse effects ; Anticoagulants/blood ; Drug Monitoring/methods ; Enoxaparin/administration & dosage ; Enoxaparin/adverse effects ; Factor Xa Inhibitors/administration & dosage ; Factor Xa Inhibitors/adverse effects ; Female ; Hemorrhage/prevention & control ; Humans ; Male ; Middle Aged ; Obesity, Morbid/blood ; Obesity, Morbid/surgery ; Pre-Exposure Prophylaxis/methods ; Retrospective Studies ; Sex Factors ; Venous Thromboembolism/blood ; Venous Thromboembolism/prevention & control
Czasopismo naukowe
Tytuł :
Application of Deep Neural Network Models in Drug Discovery Programs.
Autorzy :
Grebner C; Sanofi-Aventis Deutschland GmbH, R&D, Integrated Drug Discovery, Industriepark Höchst, 65926, Frankfurt am Main, Germany.
Matter H; Sanofi-Aventis Deutschland GmbH, R&D, Integrated Drug Discovery, Industriepark Höchst, 65926, Frankfurt am Main, Germany.
Kofink D; Sanofi-Aventis France SA, R&D, Digital & Data Science, AI and Deep Analytics, 1 Avenue Pierre Brossolette, 91380, Chilly-Mazarin, France.
Wenzel J; Sanofi-Aventis Deutschland GmbH, R&D, Preclinical Safety, Industriepark Höchst, 65926, Frankfurt am Main, Germany.
Schmidt F; Sanofi-Aventis Deutschland GmbH, R&D, Preclinical Safety, Industriepark Höchst, 65926, Frankfurt am Main, Germany.
Hessler G; Sanofi-Aventis Deutschland GmbH, R&D, Integrated Drug Discovery, Industriepark Höchst, 65926, Frankfurt am Main, Germany.
Pokaż więcej
Źródło :
ChemMedChem [ChemMedChem] 2021 Dec 14; Vol. 16 (24), pp. 3772-3786. Date of Electronic Publication: 2021 Oct 18.
Typ publikacji :
Journal Article
MeSH Terms :
Deep Learning*
Drug Discovery*
Cytochrome P-450 CYP3A/*metabolism
Cytochrome P-450 CYP3A Inhibitors/*pharmacology
Factor Xa/*metabolism
Factor Xa Inhibitors/*pharmacology
Cytochrome P-450 CYP3A Inhibitors/chemical synthesis ; Cytochrome P-450 CYP3A Inhibitors/chemistry ; Dose-Response Relationship, Drug ; Factor Xa Inhibitors/chemical synthesis ; Factor Xa Inhibitors/chemistry ; Humans ; Molecular Structure ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Screening of Potential Thrombin and Factor Xa Inhibitors from the Danshen-Chuanxiong Herbal Pair through a Spectrum-Effect Relationship Analysis.
Autorzy :
Wang X; School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 401331, China.
Zhang DY; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China.
Yin SJ; School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 401331, China.
Jiang H; School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 401331, China.
Lu M; School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 401331, China.
Yang FQ; School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 401331, China.
Hu YJ; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China.
Pokaż więcej
Źródło :
Molecules (Basel, Switzerland) [Molecules] 2021 Dec 01; Vol. 26 (23). Date of Electronic Publication: 2021 Dec 01.
Typ publikacji :
Journal Article
MeSH Terms :
Antithrombins/*pharmacology
Drugs, Chinese Herbal/*pharmacology
Factor Xa Inhibitors/*pharmacology
Thrombin/*antagonists & inhibitors
Antithrombins/chemistry ; Drug Evaluation, Preclinical ; Drugs, Chinese Herbal/chemistry ; Factor Xa Inhibitors/chemistry ; Humans ; Molecular Docking Simulation ; Salvia miltiorrhiza/chemistry
Czasopismo naukowe
Tytuł :
Direct Acting Oral Anticoagulants Following Gastrointestinal Tract Surgery.
Autorzy :
Hakeam HA; Pharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Alkhani M; Department of Vascular Surgery, Hospices Civils de Lyon, Lyon, France.
Alyahya Z; Department of Surgery, Salford Royal NHS Foundation Trust, Manchester, United Kingdom.
Alawaji Z; College of Medicine, Qassim University, Burydah, Saudi Arabia; and.
Ofori S; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Pokaż więcej
Źródło :
Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2021 Dec 01; Vol. 78 (6), pp. 867-874.
Typ publikacji :
Journal Article
MeSH Terms :
Digestive System Surgical Procedures*
Factor Xa Inhibitors/*administration & dosage
Gastrointestinal Tract/*surgery
Pyrazoles/*administration & dosage
Pyridones/*administration & dosage
Rivaroxaban/*administration & dosage
Administration, Oral ; Adult ; Aged ; Biological Availability ; Drug Monitoring ; Factor Xa Inhibitors/blood ; Factor Xa Inhibitors/pharmacokinetics ; Female ; Gastric Absorption ; Gastrointestinal Tract/metabolism ; Humans ; Intestinal Absorption ; Male ; Middle Aged ; Pyrazoles/blood ; Pyrazoles/pharmacokinetics ; Pyridones/blood ; Pyridones/pharmacokinetics ; Retrospective Studies ; Rivaroxaban/blood ; Rivaroxaban/pharmacokinetics
Czasopismo naukowe
Tytuł :
Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial.
Autorzy :
Søgaard M; Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark. Electronic address: .
Nielsen PB; Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark.
Skjøth F; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark; Unit for Clinical Biostatistics, Aalborg University Hospital, Aalborg, Denmark.
Larsen TB; Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark.
Eldrup N; Rigshospitalet, Copenhagen University, Copenhagen, Denmark; Danish Vascular Registry, Danish Regions, Aarhus, Denmark.
Pokaż więcej
Źródło :
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery [Eur J Vasc Endovasc Surg] 2022 Feb; Vol. 63 (2), pp. 285-294. Date of Electronic Publication: 2021 Dec 16.
Typ publikacji :
Journal Article
MeSH Terms :
Factor Xa Inhibitors/*administration & dosage
Peripheral Arterial Disease/*surgery
Platelet Aggregation Inhibitors/*administration & dosage
Postoperative Complications/*epidemiology
Vascular Surgical Procedures/*adverse effects
Aged ; Aspirin/administration & dosage ; Aspirin/adverse effects ; Clinical Trials, Phase III as Topic ; Denmark/epidemiology ; Dose-Response Relationship, Drug ; Drug Therapy, Combination/adverse effects ; Drug Therapy, Combination/methods ; Factor Xa Inhibitors/adverse effects ; Female ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; Multicenter Studies as Topic ; Platelet Aggregation Inhibitors/adverse effects ; Postoperative Complications/etiology ; Postoperative Complications/prevention & control ; Randomized Controlled Trials as Topic ; Rivaroxaban/administration & dosage ; Rivaroxaban/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily.
Autorzy :
Ono R; Department of Cardiology, Matsudo City General Hospital, 993-1 Sendabori, Matsudo, Chiba, 247-8533, Japan. .; Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. .
Fukushima K; Department of Cardiology, Matsudo City General Hospital, 993-1 Sendabori, Matsudo, Chiba, 247-8533, Japan.
Yamazaki T; Department of Cardiology, Matsudo City General Hospital, 993-1 Sendabori, Matsudo, Chiba, 247-8533, Japan.
Yamashita D; Department of Cardiology, Matsudo City General Hospital, 993-1 Sendabori, Matsudo, Chiba, 247-8533, Japan.
Takahashi H; Department of Cardiology, Matsudo City General Hospital, 993-1 Sendabori, Matsudo, Chiba, 247-8533, Japan.
Hori Y; Department of Cardiology, Matsudo City General Hospital, 993-1 Sendabori, Matsudo, Chiba, 247-8533, Japan.
Nishimura K; Department of Neurology, Matsudo City General Hospital, 993-1 Sendabori, Matsudo, Chiba, 247-8533, Japan.
Pokaż więcej
Źródło :
Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2022 Feb; Vol. 395 (2), pp. 159-166. Date of Electronic Publication: 2021 Dec 01.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Atrial Fibrillation/*drug therapy
Factor Xa Inhibitors/*administration & dosage
Pyrazoles/*administration & dosage
Pyridones/*administration & dosage
Venous Thromboembolism/*drug therapy
Aged ; Aged, 80 and over ; Blood Coagulation/drug effects ; Factor Xa/metabolism ; Factor Xa Inhibitors/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Partial Thromboplastin Time ; Prothrombin Time ; Pyrazoles/pharmacology ; Pyridones/pharmacology
Czasopismo naukowe
Tytuł :
Evaluation of direct oral anticoagulant use on thromboelastography in an emergency department population.
Autorzy :
Jenrette J; Department of Pharmacy, UCHealth University of Colorado Hospital, Aurora, CO, USA; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA. Electronic address: .
Schwarz K; Department of Pharmacy, UCHealth University of Colorado Hospital, Aurora, CO, USA; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA. Electronic address: .
Trujillo T; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA; Anticoagulation Services, UCHealth University of Colorado Hospital, Aurora, CO, USA. Electronic address: .
Ray L; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA; Department of Pharmacy, Denver Health, Denver, CO, USA. Electronic address: .
Pokaż więcej
Źródło :
The American journal of emergency medicine [Am J Emerg Med] 2022 Feb; Vol. 52, pp. 191-195. Date of Electronic Publication: 2021 Dec 10.
Typ publikacji :
Evaluation Study; Journal Article
MeSH Terms :
Blood Coagulation/*drug effects
Factor Xa Inhibitors/*pharmacology
Pyrazoles/*pharmacology
Pyridones/*pharmacology
Rivaroxaban/*pharmacology
Aged ; Aged, 80 and over ; Factor Xa Inhibitors/administration & dosage ; Female ; Humans ; Male ; Pyrazoles/administration & dosage ; Pyridones/administration & dosage ; Retrospective Studies ; Rivaroxaban/administration & dosage ; Thrombelastography/standards
Czasopismo naukowe
Tytuł :
Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease.
Autorzy :
Papaj K; Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Spychalska P; Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Kapica P; Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Fischer A; Department of Pharmaceutical Sciences, Computational Pharmacy, University of Basel, Basel, Switzerland.
Nowak J; Faculty of Biochemistry, Biophysics and Biotechnology, Department of Physical Biochemistry, Jagiellonian University, Krakow, Poland.
Bzówka M; Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Sellner M; Department of Pharmaceutical Sciences, Computational Pharmacy, University of Basel, Basel, Switzerland.
Lill MA; Department of Pharmaceutical Sciences, Computational Pharmacy, University of Basel, Basel, Switzerland.
Smieško M; Department of Pharmaceutical Sciences, Computational Pharmacy, University of Basel, Basel, Switzerland.
Góra A; Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2022 Jan 11; Vol. 17 (1), pp. e0262482. Date of Electronic Publication: 2022 Jan 11 (Print Publication: 2022).
Typ publikacji :
Journal Article
MeSH Terms :
Coronavirus M Proteins/*antagonists & inhibitors
Factor Xa Inhibitors/*chemistry
SARS-CoV-2/*metabolism
Benzamides/chemistry ; Benzamides/metabolism ; Binding Sites ; COVID-19/drug therapy ; COVID-19/virology ; Coronavirus M Proteins/metabolism ; Factor Xa Inhibitors/metabolism ; Humans ; Molecular Dynamics Simulation ; Protein Binding ; Protein Stability ; Pyrazoles/chemistry ; Pyrazoles/metabolism ; Pyridines/chemistry ; Pyridines/metabolism ; Pyridones/chemistry ; Pyridones/metabolism ; Rivaroxaban/chemistry ; Rivaroxaban/metabolism ; SARS-CoV-2/isolation & purification
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies